Cargando…
Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma
Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune che...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566981/ https://www.ncbi.nlm.nih.gov/pubmed/34746153 http://dx.doi.org/10.3389/fcell.2021.761758 |
_version_ | 1784594135390355456 |
---|---|
author | Xie, Xiaona Tang, Yemeng Sheng, Jueqi Shu, Pingping Zhu, Xiayan Cai, Xueding Zhao, Chengguang Wang, Liangxing Huang, Xiaoying |
author_facet | Xie, Xiaona Tang, Yemeng Sheng, Jueqi Shu, Pingping Zhu, Xiayan Cai, Xueding Zhao, Chengguang Wang, Liangxing Huang, Xiaoying |
author_sort | Xie, Xiaona |
collection | PubMed |
description | Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune checkpoint blockade (ICB) therapy, and tumor mutation burden (TMB) is a valuable independent indicator of response to immune therapy. However, specific gene mutations and their relationship with TMB and tumor-infiltrating immunocytes in LUSC are still unclear. In the present paper, our team analyzed the somatically mutated genes from the ICGC (International Cancer Genome Consortium) and TCGA (The Cancer Genome Atlas) datasets and discovered that 15 frequent gene mutations occurred in both cohorts, including ZFHX4, MUC16, FLG, TP53, LRP1B, TTN, SYNE1, RYR2, CSMD3, USH2A, MUC17, DNAH5, FAM135B, COL11A1, and RYR3. Interestingly, only mutated TTN was related to higher TMB and prognostic outcomes among the 15 mutated genes. Moreover, according to the CIBERSORT algorithm, we revealed that TTN mutation enhanced the antitumor immune response. In conclusion, TTN may have important clinical implications for relevant immune therapy of lung squamous carcinoma. |
format | Online Article Text |
id | pubmed-8566981 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-85669812021-11-05 Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma Xie, Xiaona Tang, Yemeng Sheng, Jueqi Shu, Pingping Zhu, Xiayan Cai, Xueding Zhao, Chengguang Wang, Liangxing Huang, Xiaoying Front Cell Dev Biol Cell and Developmental Biology Lung squamous cell carcinoma (LUSC) is a leading cause of mobidity and mortality worldwide. Recently, there was a shift in the treatment pattern of immune therapy in LUSC patients; merely a small number of patients with non-small cell lung cancer (NSCLC) at advanced stages respond well to immune checkpoint blockade (ICB) therapy, and tumor mutation burden (TMB) is a valuable independent indicator of response to immune therapy. However, specific gene mutations and their relationship with TMB and tumor-infiltrating immunocytes in LUSC are still unclear. In the present paper, our team analyzed the somatically mutated genes from the ICGC (International Cancer Genome Consortium) and TCGA (The Cancer Genome Atlas) datasets and discovered that 15 frequent gene mutations occurred in both cohorts, including ZFHX4, MUC16, FLG, TP53, LRP1B, TTN, SYNE1, RYR2, CSMD3, USH2A, MUC17, DNAH5, FAM135B, COL11A1, and RYR3. Interestingly, only mutated TTN was related to higher TMB and prognostic outcomes among the 15 mutated genes. Moreover, according to the CIBERSORT algorithm, we revealed that TTN mutation enhanced the antitumor immune response. In conclusion, TTN may have important clinical implications for relevant immune therapy of lung squamous carcinoma. Frontiers Media S.A. 2021-10-21 /pmc/articles/PMC8566981/ /pubmed/34746153 http://dx.doi.org/10.3389/fcell.2021.761758 Text en Copyright © 2021 Xie, Tang, Sheng, Shu, Zhu, Cai, Zhao, Wang and Huang. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Xie, Xiaona Tang, Yemeng Sheng, Jueqi Shu, Pingping Zhu, Xiayan Cai, Xueding Zhao, Chengguang Wang, Liangxing Huang, Xiaoying Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title_full | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title_fullStr | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title_full_unstemmed | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title_short | Titin Mutation Is Associated With Tumor Mutation Burden and Promotes Antitumor Immunity in Lung Squamous Cell Carcinoma |
title_sort | titin mutation is associated with tumor mutation burden and promotes antitumor immunity in lung squamous cell carcinoma |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566981/ https://www.ncbi.nlm.nih.gov/pubmed/34746153 http://dx.doi.org/10.3389/fcell.2021.761758 |
work_keys_str_mv | AT xiexiaona titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT tangyemeng titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT shengjueqi titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT shupingping titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT zhuxiayan titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT caixueding titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT zhaochengguang titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT wangliangxing titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma AT huangxiaoying titinmutationisassociatedwithtumormutationburdenandpromotesantitumorimmunityinlungsquamouscellcarcinoma |